Flexion Therapeutics (FLXN) Trading Up -1.4%

Flexion Therapeutics Inc (NASDAQ:FLXN) shares were up 1.4% on Wednesday . The stock traded as high as $23.92 and last traded at $23.46. Approximately 322,820 shares changed hands during mid-day trading, a decline of 54% from the average daily volume of 705,834 shares. The stock had previously closed at $23.80.

Several research analysts have weighed in on FLXN shares. Wells Fargo & Co set a $39.00 price target on Flexion Therapeutics and gave the company a “buy” rating in a report on Monday, October 30th. Zacks Investment Research downgraded Flexion Therapeutics from a “hold” rating to a “sell” rating in a report on Tuesday, October 17th. ValuEngine upgraded Flexion Therapeutics from a “sell” rating to a “hold” rating in a report on Monday. BidaskClub downgraded Flexion Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, January 20th. Finally, Northland Securities restated a “buy” rating and set a $40.00 price objective on shares of Flexion Therapeutics in a report on Friday, November 10th. Two investment analysts have rated the stock with a sell rating, two have issued a hold rating and eight have issued a buy rating to the company’s stock. Flexion Therapeutics presently has an average rating of “Buy” and an average price target of $99.11.

The firm has a market capitalization of $846.17, a price-to-earnings ratio of -6.40 and a beta of 0.91. The company has a debt-to-equity ratio of 0.87, a current ratio of 12.93 and a quick ratio of 12.93.

Flexion Therapeutics (NASDAQ:FLXN) last released its quarterly earnings data on Monday, November 6th. The specialty pharmaceutical company reported ($1.07) EPS for the quarter, missing analysts’ consensus estimates of ($0.98) by ($0.09). research analysts anticipate that Flexion Therapeutics Inc will post -3.84 earnings per share for the current fiscal year.

In other Flexion Therapeutics news, insider Neil Bodick purchased 2,700 shares of the firm’s stock in a transaction that occurred on Tuesday, November 21st. The stock was purchased at an average cost of $24.49 per share, with a total value of $66,123.00. Following the transaction, the insider now owns 64,605 shares in the company, valued at $1,582,176.45. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 15.98% of the stock is currently owned by corporate insiders.

Institutional investors have recently made changes to their positions in the stock. Advisory Services Network LLC purchased a new stake in Flexion Therapeutics during the 4th quarter worth $108,000. Advisor Group Inc. boosted its position in Flexion Therapeutics by 205.9% during the 2nd quarter. Advisor Group Inc. now owns 5,200 shares of the specialty pharmaceutical company’s stock worth $105,000 after purchasing an additional 3,500 shares during the period. SG Americas Securities LLC purchased a new stake in Flexion Therapeutics during the 3rd quarter worth $135,000. IFP Advisors Inc boosted its position in Flexion Therapeutics by 58.1% during the 3rd quarter. IFP Advisors Inc now owns 8,030 shares of the specialty pharmaceutical company’s stock worth $194,000 after purchasing an additional 2,950 shares during the period. Finally, State Board of Administration of Florida Retirement System purchased a new stake in Flexion Therapeutics during the 3rd quarter worth $235,000. 73.21% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION NOTICE: This piece was first reported by Community Financial News and is the property of of Community Financial News. If you are viewing this piece on another site, it was illegally copied and reposted in violation of U.S. & international trademark & copyright legislation. The legal version of this piece can be read at https://www.com-unik.info/2018/02/09/flexion-therapeutics-flxn-trading-up-1-4.html.

About Flexion Therapeutics

Flexion Therapeutics, Inc is a United States-based specialty pharmaceutical company. The Company is focused on the development and commercialization of local therapies for the treatment of patients with musculoskeletal conditions, beginning with osteoarthritis (OA), a type of degenerative arthritis. The Company’s lead product candidate, Zilretta, is a late-stage, injectable, extended-release, intra-articular (IA) investigational steroid.

Receive News & Ratings for Flexion Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Flexion Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit